Compare Toronto-Dominion Bank (TD) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Toronto-Dominion Bank vs GeneDx Holdings Corp — how do they compare? Toronto-Dominion Bank trades at $119.29 (market cap $197.22B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). The key difference: Toronto-Dominion Bank is far larger — about 77× GeneDx Holdings Corp's market cap, and Toronto-Dominion Bank pays a 2.69% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| TD | WGS | |
|---|---|---|
Market Cap | $197.22B | $2.56B |
Sector | Financials | Technology |
52-Week High | $124.80 | $167.51 |
52-Week Low | $75.86 | $34.51 |
Dividend Yield | 2.69% | — |
Enterprise Value | — | $2.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TD trades at $120.52, down 0.91% on the day, with a neutral technical signal. The company reported strong Q3 2026 earnings of $2.74 EPS, beating estimates, driven by capital markets performance and cost controls. Revenue growth continues with 2025 revenue reaching $61.28B and net income margin of 33.51%. Analyst consensus is bullish with 9 buy ratings and no sell recommendations.
TD presents a compelling investment case with consistent earnings beats and strong profitability metrics. However, investors should monitor the volatile cash flow patterns and rising debt-to-asset ratio, which increased to 22.1 in 2024. The stock's current valuation at 17.85 P/E appears reasonable given the company's growth trajectory and dividend yield.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
